RELUGOLIX

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H27F2N7O5S
Molecular Weight	623.63
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CONC(=O)NC1=CC=C(C=C1)C2=C(CN(C)C)C3=C(S2)N(CC4=C(F)C=CC=C4F)C(=O)N(C3=O)C5=CC=C(OC)N=N5

InChI

InChIKey=AOMXMOCNKJTRQP-UHFFFAOYSA-N

InChI=1S/C29H27F2N7O5S/c1-36(2)14-19-24-26(39)38(22-12-13-23(42-3)34-33-22)29(41)37(15-18-20(30)6-5-7-21(18)31)27(24)44-25(19)16-8-10-17(11-9-16)32-28(40)35-43-4/h5-13H,14-15H2,1-4H3,(H2,32,35,40)

HIDE SMILES / InChI

Molecular Formula	C29H27F2N7O5S
Molecular Weight	623.63
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/30937733 | https://www.ncbi.nlm.nih.gov/pubmed/26502357 | https://clinicaltrials.gov/ct2/show/NCT01989234 | https://clinicaltrials.gov/ct2/show/results/NCT02655237

Relugolix (TAK-385) is an orally active nonpeptide gonadotropin-releasing hormone (GnRH) that binds to human GnRH receptors with subnanomolar affinity. Relugolix was demonstrated to act as a classic competitive antagonist of GnRH binding, but the exact molecular mechanism of that antagonism remains unknown. This drug is being developed as a treatment for various sex hormone related disorders. Clinical trials have been conducted to study safety and efficacy of relugolix as a treatment in endometriosis, uterine fibroids (noncancerous growths of the uterus), and prostate cancer. Two phase III trials evaluating the efficacy of Relugolix in patients with uterine fibroids were completed in 2019. No serious adverse events were reported.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Gonadotropin-releasing hormone receptor 40 Target ID: CHEMBL1855 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21657270	Antagonist 2737		0.08 nM [IC50]

PubMed

Title	Date	PubMed
Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor.	2011 Jul 28	21657270

Substance Class	Chemical Created by `admin` on `Sat Dec 17 06:45:13 UTC 2022` Edited by `admin` on `Sat Dec 17 06:45:13 UTC 2022`
Record UNII	P76B05O5V6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RELUGOLIX

Official Name

English

MYFEMBREE COMPONENT RELUGOLIX

Brand Name

English

RELUGOLIX COMPONENT OF MYFEMBREE

Brand Name

English

Relugolix [WHO-DD]

Common Name

English

RELUGOLIX [JAN]

Common Name

English

TAK-385

Code

English

relugolix [INN]

Common Name

English

RELUGOLIX [ORANGE BOOK]

Common Name

English Albanian

UREA, N-(4-(1-((2,6-DIFLUOROPHENYL)METHYL)-5-((DIMETHYLAMINO)METHYL)-1,2,3,4-TETRAHYDRO-3-(6-METHOXY-3-PYRIDAZINYL)-2,4-DIOXOTHIENO(2,3-D)PYRIMIDIN-6-YL)PHENYL)-N'-METHOXY-

Systematic Name

English

ORGOVYX

Brand Name

English

1-(4-{1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}phenyl)-3-methoxyurea

Systematic Name

English

RELUGOLIX [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C63347